Concise Prescribing Info
Lisdexamfetamine dimesylate
Dosage/Direction for Use
Patient ≥6 yr Recommended starting dose: 30 mg once daily in the morning. Dose may be adjusted in increments of 10 or 20 mg at approx wkly intervals. Max: 70 mg/day. Patient w/ severe renal impairment (GFR 15-<30 mL/min/1.73 m2) Max: 50 mg/day. Patient w/ end stage renal disease (GFR <15 mL/min/1.73 m2) Max: 30 mg/day.
May be taken with or without food.
Hypersensitivity. Patients taking MAOIs or w/in 14 days of stopping MAOIs (including linezolid, IV methylene blue).
Special Precautions
Not indicated or recommended for wt loss. Assess risk of abuse prior to prescribing; monitor for signs of abuse & dependence while on therapy. Associated w/ serious CV adverse events; assess for cardiac disease presence prior to treatment initiation. Monitor all patients for potential tachycardia & HTN. May exacerbate symptoms of behavior disturbance & thought disorder in patients w/ pre-existing psychotic disorder. May induce a mixed/manic episode in patients w/ bipolar disorder. May cause psychotic or manic symptoms in childn & adolescents w/o prior history of psychotic illness or mania. Closely monitor growth (wt & height) in ped patients. Associated w/ peripheral vasculopathy, including Raynaud's phenomenon; carefully observe for digital changes during treatment. Immediately discontinue treatment & any concomitant serotonergic agents & initiate supportive symptomatic treatment if symptoms of serotonin syndrome occur. Not dialyzable. Increased risk of premature delivery & low birth wt for infants born to amphetamine-dependent mothers. Monitor infants for w/drawal symptoms eg, feeding difficulties, irritability, agitation, & excessive drowsiness. Breastfeeding is not recommended during treatment. Childn <6 yr. Elderly >65 yr.
Adverse Reactions
Anorexia, anxiety, decreased appetite & wt, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting.
Drug Interactions
Increased risk of hypertensive crisis w/ MAOIs eg, selegiline, isocarboxazid, phenelzine, tranylcypromine. Increased risk of serotonin syndrome w/ serotonergic drugs eg, SSRIs, serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, TCAs, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort. Increased exposure w/ CYP2D6 inhibitors eg, paroxetine & fluoxetine, quinidine, ritonavir. Increased blood levels & potentiated action w/ urinary alkalinizing agents eg, acetazolamide, some thiazides. Decreased blood levels & efficacy w/ urinary acidifying agents eg, ammon Cl, Na acid phosphate, methenamine salts. Increased brain conc & potentiated CV effects w/ TCAs eg, desipramine, protriptyline.
ATC Classification
N06BA12 - lisdexamfetamine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Vyvanse cap 30 mg
Vyvanse cap 20 mg
Vyvanse cap 50 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in